檢索結果 - Shude Cui

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status

    miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status 由 Zhen-Duo Lu, Yuping Ye, Dechuang Jiao, Jian-Hua Qiao, Shude Cui, Zhenzhen Liu

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties

    Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties 由 Hui Liu, Hengwei Zhang, Xianfu Sun, Xuhui Guo, Yaning He, Shude Cui, Qing-Xia Fan

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial

    Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial 由 Peng Yuan, Xichun Hu, Tao Sun, Wei Li, Qingyuan Zhang, Shude Cui, Ying Cheng, Quchang Ouyang, Xiaojia Wang, Zhendong Chen, Masahide Hiraiwa, Kenichi Saito, Setsuo Funasaka, Binghe Xu

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals

    Current Status and Factors Influencing Surgical Options for Breast Cancer in China: A Nationwide Cross-Sectional Survey of 110 Hospitals 由 Benlong Yang, Guosheng Ren, Erwei Song, Da Pan, Jing Zhang, Yongsheng Wang, Ning Liao, Jinhai Tang, Xiang Wang, Shude Cui, Feng Jin, Cuizhi Geng, Qiang Sun, Hongyuan Li, Zhimin Fan, Xuchen Cao, Haibo Wang, Shu Wang, Zhimin Shao, Jiong Wu

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Primary results from PALOMA-4

    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced b... 由 Binghe Xu, Xichun Hu, Wěi Li, Tao Sun, Kunwei Shen, Shusen Wang, Ying Cheng, Qingyuan Zhang, Shude Cui, Zhongsheng Tong, Cuizhi Geng, Erwei Song, Chiun‐Sheng Huang, Virote Sriuranpong, Roger K.C. Ngan, Yee Hong Chia, Xinwei Wang, Huadong Zhao

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

    Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia 由 Zhimin Shao, Da Pang, Hongjian Yang, Wěi Li, Shusen Wang, Shude Cui, Ning Liao, Yongsheng Wang, Chuan Wang, Yuan-Ching Chang, Hweichung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Junjie Li, Julian Q. Zhou, Betsy Althaus, Yixiang Mao, Jennifer Eng‐Wong

    出版 2019
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial

    Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial 由 Liang Huang, Da Pang, Hongjian Yang, Wei Li, Shusen Wang, Shude Cui, Ning Liao, Yongsheng Wang, Chuan Wang, Yuan‐Ching Chang, Hwei-Chung Wang, Seok Yun Kang, Jae Hong Seo, Kunwei Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Haiyan Wang, François Lamour, Grace Y. Song, Michelle Curran, Chunzhe Duan, Sanne Lysbet de Haas, Eleonora Restuccia, Zhimin Shao

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

    Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial 由 Junjie Li, Ke‐Da Yu, Da Pang, Changqin Wang, Jun Jiang, Suisheng Yang, Yunjiang Liu, Peifen Fu, Yuan Sheng, Guo‐Jun Zhang, Yali Cao, Qi He, Shude Cui, Xi-Jing Wang, Guosheng Ren, Xinzheng Li, Shiyou Yu, Pengxi Liu, Xiang Qu, Jinhai Tang, Ouchen Wang, Zhimin Fan, Guoqin Jiang, Jin Zhang, Jiandong Wang, Hongwei Zhang, Shui Wang, Jianguo Zhang, Feng Jin, Nanyan Rao, Binlin Ma, Pingqing He, Binghe Xu, Zhigang Zhuang, Jianfeng Wang, Qiang Sun, Xiaofeng Guo, Miao Mo, Zhimin Shao

    出版 2020
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: